Elicio Therapeutics, a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, has announced the pricing of an underwritten public offering worth approximately $11.5 million. The offering includes common stock and accompanying warrants to purchase common stock. After deducting underwriting discounts, commissions, and offering expenses, Elicio expects to raise funds for advancing its pipeline of novel therapies.
In addition, Elicio Therapeutics has reported a significant improvement in its Leverage Ratio, which measures the company’s level of debt relative to its assets. Despite net new borrowings of 24.33%, the Leverage Ratio has fallen to 4.03, marking a new company high. However, compared to other companies in the industry, Elicio’s Leverage Ratio is relatively high, with 203 companies reporting lower ratios for the first quarter of 2024.
When considering the company’s ranking among all reported Leverage Ratios, Elicio’s position has deteriorated from 1.39 in the fourth quarter of 2023 to 2063. Nonetheless, Elicio Therapeutics has achieved an all-time high Leverage Ratio of 1.26 during the trailing twelve months, showcasing its improved financial performance. This ratio is also the lowest within the industry.
Over the past twelve months, Elicio has consistently enhanced its ranking for Leverage Ratio, rising from 1602 in the fourth quarter of 2023 to an impressive ranking of 5.
Comments